1. Home
  2. OBIO vs BLFY Comparison

OBIO vs BLFY Comparison

Compare OBIO & BLFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBIO
  • BLFY
  • Stock Information
  • Founded
  • OBIO 2017
  • BLFY 1939
  • Country
  • OBIO United States
  • BLFY United States
  • Employees
  • OBIO N/A
  • BLFY N/A
  • Industry
  • OBIO Medicinal Chemicals and Botanical Products
  • BLFY Commercial Banks
  • Sector
  • OBIO Health Care
  • BLFY Finance
  • Exchange
  • OBIO Nasdaq
  • BLFY Nasdaq
  • Market Cap
  • OBIO 172.1M
  • BLFY 185.3M
  • IPO Year
  • OBIO N/A
  • BLFY N/A
  • Fundamental
  • Price
  • OBIO $4.24
  • BLFY $7.80
  • Analyst Decision
  • OBIO Strong Buy
  • BLFY Hold
  • Analyst Count
  • OBIO 4
  • BLFY 1
  • Target Price
  • OBIO $13.67
  • BLFY $10.00
  • AVG Volume (30 Days)
  • OBIO 301.5K
  • BLFY 51.0K
  • Earning Date
  • OBIO 11-10-2025
  • BLFY 10-29-2025
  • Dividend Yield
  • OBIO N/A
  • BLFY N/A
  • EPS Growth
  • OBIO N/A
  • BLFY N/A
  • EPS
  • OBIO N/A
  • BLFY N/A
  • Revenue
  • OBIO $2,818,000.00
  • BLFY $44,731,000.00
  • Revenue This Year
  • OBIO $31.43
  • BLFY $19.85
  • Revenue Next Year
  • OBIO $10.87
  • BLFY $20.18
  • P/E Ratio
  • OBIO N/A
  • BLFY N/A
  • Revenue Growth
  • OBIO 6.46
  • BLFY 11.52
  • 52 Week Low
  • OBIO $2.20
  • BLFY $7.79
  • 52 Week High
  • OBIO $6.30
  • BLFY $11.38
  • Technical
  • Relative Strength Index (RSI)
  • OBIO 63.87
  • BLFY 27.99
  • Support Level
  • OBIO $3.86
  • BLFY $8.05
  • Resistance Level
  • OBIO $4.02
  • BLFY $8.33
  • Average True Range (ATR)
  • OBIO 0.30
  • BLFY 0.22
  • MACD
  • OBIO 0.00
  • BLFY -0.04
  • Stochastic Oscillator
  • OBIO 89.22
  • BLFY 0.00

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

About BLFY Blue Foundry Bancorp

Blue Foundry Bancorp is a full-service bank. Its business consists of originating one-to-four-family residential, multi-family, and non-residential real estate mortgages, home equity loans and lines of credit, and commercial and industrial loans. It attracts retail deposits from the general public in the areas surrounding its banking offices, through its borrowers, and through its online presence, offering a wide variety of deposit products. The bank also invests in securities. Its revenues are derived from interest on loans and, to a lesser extent, interest on mortgage-backed and other investment securities. The company's sources of funds are deposits, principal, and interest payments on loans, securities, and borrowings from the Federal Home Loan Bank of New York.

Share on Social Networks: